Barbara M Gruner
Overview
Explore the profile of Barbara M Gruner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cai L, Gao Y, DeBerardinis R, Acquaah-Mensah G, Aidinis V, Beane J, et al.
bioRxiv
. 2024 Mar;
PMID: 38464291
Lung cancer, the leading cause of cancer mortality, exhibits diverse histological subtypes and genetic complexities. Numerous preclinical mouse models have been developed to study lung cancer, but data from these...
2.
Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull H, Cima I, et al.
iScience
. 2024 Jan;
27(1):108596.
PMID: 38174322
Adaptive plasticity to the standard chemotherapeutic temozolomide (TMZ) leads to glioblastoma progression. Here, we examine early stages of this process in patient-derived cellular models, exposing the human lysine-specific demethylase 5B...
3.
Zecha J, Bayer F, Wiechmann S, Woortman J, Berner N, Muller J, et al.
Science
. 2023 Mar;
380(6640):93-101.
PMID: 36926954
Although most cancer drugs modulate the activities of cellular pathways by changing posttranslational modifications (PTMs), little is known regarding the extent and the time- and dose-response characteristics of drug-regulated PTMs....
4.
Kebir S, Ullrich V, Berger P, Dobersalske C, Langer S, Rauschenbach L, et al.
Clin Cancer Res
. 2022 Oct;
29(2):488-500.
PMID: 36239995
Purpose: Therapy resistance and fatal disease progression in glioblastoma are thought to result from the dynamics of intra-tumor heterogeneity. This study aimed at identifying and molecularly targeting tumor cells that...
5.
Dorsch M, Kowalczyk M, Planque M, Heilmann G, Urban S, Dujardin P, et al.
Cell Rep
. 2021 Nov;
37(8):110056.
PMID: 34818551
Statins are among the most commonly prescribed drugs, and around every fourth person above the age of 40 is on statin medication. Therefore, it is of utmost clinical importance to...
6.
Ho C, Tuns A, Schildhaus H, Wiesweg M, Gruner B, Hegedus B, et al.
Eur J Cancer
. 2021 Oct;
159:16-23.
PMID: 34715459
Introduction: Mutant RAS guanosine triphosphate hydrolases (GTPases) are key oncogenic drivers in many cancers. The KRAS variant has recently become targetable by a new drug class specifically locking KRAS in...
7.
Dujardin P, Baginska A, Urban S, Gruner B
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439341
Tumor heterogeneity is a hallmark of many solid tumors, including pancreatic ductal adenocarcinoma (PDAC), and an inherent consequence of the clonal evolution of cancers. As such, it is considered the...
8.
Dujardin P, Gruner B
Methods Mol Biol
. 2021 Mar;
2294:239-251.
PMID: 33742406
DNA barcoding allows the quantitative, biomarker-free tracking of individual cell populations in mixed/heterogeneous cell pools. Here, we describe a multiplexed in vivo screening platform based on DNA barcoding technology to...
9.
Chuang C, Dorsch M, Dujardin P, Silas S, Ueffing K, Holken J, et al.
Cancer Res
. 2020 Nov;
81(3):567-579.
PMID: 33239425
Lung cancer is a prevalent and lethal cancer type that leads to more deaths than the next four major cancer types combined. Metastatic cancer spread is responsible for most cancer-related...
10.
Nothdurft S, Thumser-Henner C, Breitenbucher F, Okimoto R, Dorsch M, Opitz C, et al.
Oncogenesis
. 2020 Nov;
9(11):102.
PMID: 33214553
Lung cancer mortality largely results from metastasis. Despite curative surgery many patients with early-stage non-small cell lung cancer ultimately succumb to metastatic relapse. Current risk reduction strategies based on cytotoxic...